Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma

Nishant Tageja, Neha Korde, Dickran Kazandjian, Sandhya Panch, Elisabet Manasanch, Manisha Bhutani, Mary Kwok, Sham Mailankody, Constance Yuan, Maryalice Stetler-Stevenson, Susan F. Leitman, Claude Sportes, Ola Landgren

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regiments, most patients had residual myeloma cells in their autologous stem-cell grafts during collection. Emerging data show that newly diagnosed multiple myeloma patients treated with modern carfilzomib/lenalidomide/dexamethasone (KRd) therapy, on average, take 6 cycles until reaching minimal residual disease (MRD) negativity. We assessed newly diagnosed patients treated with KRd focusing MRD status both in the individual patient’s bone marrow, and the corresponding autologous hematopoietic progenitor cell grafts during collection. Per protocol, stem-cell collection was allowed after 4 to 8 cycles of KRd. We found similar stem-cell yield independent of the number of cycles of KRd. At stem-cell collection, 11/30 patients (36.6%) were MRD negative in their bone marrow; all 11 patients had MRD negative hematopoietic progenitor cell grafts. Furthermore, 18/19 patients who were MRD positive in their bone marrows also had MRD negative hematopoietic progenitor cell grafts. These observations support 6 cycles of KRd as an efficacious and safe induction strategy prior to stem-cell collection.

Original languageEnglish (US)
Pages (from-to)1445-1449
Number of pages5
JournalBone marrow transplantation
Volume53
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Dexamethasone
Residual Neoplasm
Stem Cells
Transplants
Hematopoietic Stem Cells
Bone Marrow
Therapeutics
Multiple Myeloma
carfilzomib
lenalidomide
Doxorubicin
Physicians

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. / Tageja, Nishant; Korde, Neha; Kazandjian, Dickran; Panch, Sandhya; Manasanch, Elisabet; Bhutani, Manisha; Kwok, Mary; Mailankody, Sham; Yuan, Constance; Stetler-Stevenson, Maryalice; Leitman, Susan F.; Sportes, Claude; Landgren, Ola.

In: Bone marrow transplantation, Vol. 53, No. 11, 01.11.2018, p. 1445-1449.

Research output: Contribution to journalArticle

Tageja, N, Korde, N, Kazandjian, D, Panch, S, Manasanch, E, Bhutani, M, Kwok, M, Mailankody, S, Yuan, C, Stetler-Stevenson, M, Leitman, SF, Sportes, C & Landgren, O 2018, 'Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma', Bone marrow transplantation, vol. 53, no. 11, pp. 1445-1449. https://doi.org/10.1038/s41409-018-0170-0
Tageja, Nishant ; Korde, Neha ; Kazandjian, Dickran ; Panch, Sandhya ; Manasanch, Elisabet ; Bhutani, Manisha ; Kwok, Mary ; Mailankody, Sham ; Yuan, Constance ; Stetler-Stevenson, Maryalice ; Leitman, Susan F. ; Sportes, Claude ; Landgren, Ola. / Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. In: Bone marrow transplantation. 2018 ; Vol. 53, No. 11. pp. 1445-1449.
@article{4de664c4ca14475c9008492319fef35a,
title = "Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma",
abstract = "Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regiments, most patients had residual myeloma cells in their autologous stem-cell grafts during collection. Emerging data show that newly diagnosed multiple myeloma patients treated with modern carfilzomib/lenalidomide/dexamethasone (KRd) therapy, on average, take 6 cycles until reaching minimal residual disease (MRD) negativity. We assessed newly diagnosed patients treated with KRd focusing MRD status both in the individual patient’s bone marrow, and the corresponding autologous hematopoietic progenitor cell grafts during collection. Per protocol, stem-cell collection was allowed after 4 to 8 cycles of KRd. We found similar stem-cell yield independent of the number of cycles of KRd. At stem-cell collection, 11/30 patients (36.6{\%}) were MRD negative in their bone marrow; all 11 patients had MRD negative hematopoietic progenitor cell grafts. Furthermore, 18/19 patients who were MRD positive in their bone marrows also had MRD negative hematopoietic progenitor cell grafts. These observations support 6 cycles of KRd as an efficacious and safe induction strategy prior to stem-cell collection.",
author = "Nishant Tageja and Neha Korde and Dickran Kazandjian and Sandhya Panch and Elisabet Manasanch and Manisha Bhutani and Mary Kwok and Sham Mailankody and Constance Yuan and Maryalice Stetler-Stevenson and Leitman, {Susan F.} and Claude Sportes and Ola Landgren",
year = "2018",
month = "11",
day = "1",
doi = "10.1038/s41409-018-0170-0",
language = "English (US)",
volume = "53",
pages = "1445--1449",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma

AU - Tageja, Nishant

AU - Korde, Neha

AU - Kazandjian, Dickran

AU - Panch, Sandhya

AU - Manasanch, Elisabet

AU - Bhutani, Manisha

AU - Kwok, Mary

AU - Mailankody, Sham

AU - Yuan, Constance

AU - Stetler-Stevenson, Maryalice

AU - Leitman, Susan F.

AU - Sportes, Claude

AU - Landgren, Ola

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regiments, most patients had residual myeloma cells in their autologous stem-cell grafts during collection. Emerging data show that newly diagnosed multiple myeloma patients treated with modern carfilzomib/lenalidomide/dexamethasone (KRd) therapy, on average, take 6 cycles until reaching minimal residual disease (MRD) negativity. We assessed newly diagnosed patients treated with KRd focusing MRD status both in the individual patient’s bone marrow, and the corresponding autologous hematopoietic progenitor cell grafts during collection. Per protocol, stem-cell collection was allowed after 4 to 8 cycles of KRd. We found similar stem-cell yield independent of the number of cycles of KRd. At stem-cell collection, 11/30 patients (36.6%) were MRD negative in their bone marrow; all 11 patients had MRD negative hematopoietic progenitor cell grafts. Furthermore, 18/19 patients who were MRD positive in their bone marrows also had MRD negative hematopoietic progenitor cell grafts. These observations support 6 cycles of KRd as an efficacious and safe induction strategy prior to stem-cell collection.

AB - Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regiments, most patients had residual myeloma cells in their autologous stem-cell grafts during collection. Emerging data show that newly diagnosed multiple myeloma patients treated with modern carfilzomib/lenalidomide/dexamethasone (KRd) therapy, on average, take 6 cycles until reaching minimal residual disease (MRD) negativity. We assessed newly diagnosed patients treated with KRd focusing MRD status both in the individual patient’s bone marrow, and the corresponding autologous hematopoietic progenitor cell grafts during collection. Per protocol, stem-cell collection was allowed after 4 to 8 cycles of KRd. We found similar stem-cell yield independent of the number of cycles of KRd. At stem-cell collection, 11/30 patients (36.6%) were MRD negative in their bone marrow; all 11 patients had MRD negative hematopoietic progenitor cell grafts. Furthermore, 18/19 patients who were MRD positive in their bone marrows also had MRD negative hematopoietic progenitor cell grafts. These observations support 6 cycles of KRd as an efficacious and safe induction strategy prior to stem-cell collection.

UR - http://www.scopus.com/inward/record.url?scp=85046409989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046409989&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0170-0

DO - 10.1038/s41409-018-0170-0

M3 - Article

C2 - 29728700

AN - SCOPUS:85046409989

VL - 53

SP - 1445

EP - 1449

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -